Le mésothéliome pleural malin

J. Margery; D. Planchard

doi:10.1007/s10269-014-2395-x

Le mésothéliome pleural malin

J. Margery, D. Planchard

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

Résumé

Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology and on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab was tested in an randomized phase 3 trial, MAPS, until December 2013.

Titre traduit de la contribution	Malignant pleural mesothelioma
langue originale	Français
Pages (de - à)	245-249
Nombre de pages	5
journal	Oncologie
Volume	16
Numéro de publication	5
Les DOIs	https://doi.org/10.1007/s10269-014-2395-x
état	Publié - 1 janv. 2014
Modification externe	Oui

mots-clés

Asbestosis
Diagnosis
Mesothelioma
Pleura
Treatment

Accès au document

10.1007/s10269-014-2395-x

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{b34e4f360bdf461e8c56062fff8bea2b,

title = "Le m{\'e}soth{\'e}liome pleural malin",

abstract = "Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology and on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab was tested in an randomized phase 3 trial, MAPS, until December 2013.",

keywords = "Asbestosis, Diagnosis, Mesothelioma, Pleura, Treatment",

author = "J. Margery and D. Planchard",

year = "2014",

month = jan,

day = "1",

doi = "10.1007/s10269-014-2395-x",

language = "Fran{\c c}ais",

volume = "16",

pages = "245--249",

journal = "Oncologie",

issn = "1292-3818",

number = "5",

}

TY - JOUR

T1 - Le mésothéliome pleural malin

AU - Margery, J.

AU - Planchard, D.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology and on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab was tested in an randomized phase 3 trial, MAPS, until December 2013.

AB - Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology and on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab was tested in an randomized phase 3 trial, MAPS, until December 2013.

KW - Asbestosis

KW - Diagnosis

KW - Mesothelioma

KW - Pleura

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84902546550&partnerID=8YFLogxK

U2 - 10.1007/s10269-014-2395-x

DO - 10.1007/s10269-014-2395-x

M3 - Article 'review'

AN - SCOPUS:84902546550

SN - 1292-3818

VL - 16

SP - 245

EP - 249

JO - Oncologie

JF - Oncologie

IS - 5

ER -